Author
Li, J.; Sparkenbaugh, E.; Su, G.; Zhang, F.; Xu, Y.; Xia, K.; He, P.; Baytas, S.; Pechauer, S.; Padmanabhan, A.; Linhardt, Robert J.; Pawlinski, R.; Liu, J.
Other Contributors
Date Issued
2020
Subject
Biology; Chemistry and chemical biology; Chemical and biological engineering; Biomedical engineering
Degree
Terms of Use
In Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/;
Full Citation
Enzymatic synthesis of chondroitin sulfate E to attenuate bacterial lipopolysaccharide-induced organ damage J. Li, E. Sparkenbaugh, G. Su, F. Zhang, Y. Xu, K. Xia, P. He, S. Baytas, S. Pechauer, A. Padmanabhan, R. J. Linhardt, R. Pawlinski, J. Liu, ACS Central Science, 6, 1199−1207, 2020.
Abstract
Chondroitin sulfate E (CS-E) is a sulfated polysaccharide that contains repeating disaccharides of 4,6-disulfated N-acetylgalactosamine and glucuronic acid residues. Here, we report the enzymatic synthesis of three homogeneous CS-E oligosaccharides, including CS-E heptasaccharide (CS-E 7-mer), CS-E tridecasaccharide (CS-E13-mer), and CS-E nonadecasaccharide (CS-E 19-mer). The anti-inflammatory effect of CS-E 19-mer was investigated in this study. CS-E 19-mer neutralizes the cytotoxic effect of histones in a cell-based assay and in mice. We also demonstrate that CS-E 19-mer treatment improves survival and protects against organ damage in a mouse model of endotoxemia induced by bacterial lipopolysaccharide (LPS). CS-E19-mer directly interacts with circulating histones in the plasma from LPS-challenged mice. CS-E 19-mer does not display anticoagulant activity nor react with heparin-induced thrombocytopenia antibodies isolated from patients. The successful synthesis of CS-E oligosaccharides provides structurally defined carbohydrates for advancing CS-E research and offers a potential therapeutic agent to treat life-threatening systemic inflammation.;
Description
ACS Central Science, 6, 1199−1207; Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Department
The Linhardt Research Labs.; The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS);
Publisher
American Chemical Society (ACS)
Relationships
The Linhardt Research Labs Online Collection; Rensselaer Polytechnic Institute, Troy, NY; https://harc.rpi.edu/;
Access
ACS AuthorChoice License; A full text version is available in DSpace@RPI;
